Biopharma Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–12 of 54 articles
Eli Lilly pipeline and deals: GLP-1, vaccines, and 2026 outlook
diabetes · 7 min
Dr. Sarah MitchellMcGuireWoods' Alyssa Campbell Honored in M&A Advisor Emerging Leaders Awards
5 min
Dr. Sarah MitchellOtsuka kidney drug data and Pfizer AI deal: Biopharma deal tracker
IgA nephropathy · 8 min
Dr. Sarah MitchellHHS Confirms Americans with High-Risk Ebola Exposures Will Have Access to Experimental Therapy MBP-134
HHS · Ebola · 4 min
Dr. Sarah MitchellChina: The Innovation Factor – Implications for Pharma BD and Investors
6 min
Dr. Sarah MitchellUtah Medical Board Scolded for Going Rogue with AI Criticism: Deal Implications for Pharma
6 min
Dr. Sarah MitchellMercury Acquires King Courier to Grow Bay Area Logistics: Deal Intelligence for Pharma Teams
5 min
Dr. Sarah MitchellBest Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner
6 min
Dr. Sarah MitchellHouse bill aims to crack down on China biotech deals
5 min
Dr. Sarah MitchellASCO Summit: Ivonescimab's China Lung Data Shows Promise, But Global Validation Remains Key
lung · 8 min
Dr. Sarah MitchellCG Life Appoints Collette Douaihy Chief Creative Officer to Drive Biopharma Marketing Innovation
FDA · 9 min
Dr. Sarah MitchellSTAT+ R&D Performance Ranking: Insights for Pharma Companies
FDA · 7 min
Dr. Sarah MitchellExplore intelligence